
- Relmada Therapeutics (RLMD) is a clinical-stage pharma company with no commercialized products and a $141 million market cap.
- RLMD has shown strong technical momentum, gaining 440% since August.
- Shares have a 100% “Buy” technical opinion from Barchart.
- Despite technical strength, RLMD lacks revenue, faces pipeline setbacks, and is rated “Hold” on Wall Street.
Author’s Note: Investments are judged by revenue, earnings, cash flow, and dividends – that’s Investing 101. This company was founded in 2004 and, 21 years later, has never sold a dime of product. This is not investing. This is speculation. Two words: Due Diligence